Takeda Pharmaceutical Company
Logotype for Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company (4502) investor relations material

Takeda Pharmaceutical Company Q2 2027 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Takeda Pharmaceutical Company Limited
Q2 2027 earnings summary29 Oct, 2026

Executive summary

  • H1 FY2026 revenue was JPY 2,407.0B, up 8.4% reported but down 1.0% CER; core operating profit rose 11.2% reported and 0.7% CER to JPY 710.6B.

  • Transformation savings helped fund launches and R&D; FY2026 core operating profit guidance increased to JPY 1,190B, mainly on FX benefits.

Financial highlights

  • H1 reported operating profit rose 60.4% to JPY 406.7B; net profit attributable to owners was JPY 305.6B, up 171.8% reported.

  • H1 core net profit was JPY 489.6B, up 11.6% reported and down 0.2% CER; core EPS was JPY 308, up 10.5% reported and down 1.2% CER.

  • Q2 revenue was JPY 1,187.1B, down 1.6% CER; core operating profit was JPY 351.7B, up 1.9% CER.

  • H1 operating cash flow was JPY 431.9B, down 27.2%; adjusted free cash flow was JPY 325.7B, down 38.0%.

Outlook and guidance

  • FY2026 revenue guidance rose JPY 60B to JPY 4,700B; the low-single-digit CER decline outlook was maintained.

  • Core operating profit guidance increased JPY 30B to JPY 1,190B and core EPS to JPY 482, mainly reflecting transactional FX benefits.

  • Reported operating profit guidance rose to JPY 453B, net profit to JPY 209B and basic EPS to JPY 131; adjusted FCF guidance increased to JPY 700B–800B.

  • CER guidance indicates mid-single-digit core operating profit decline and low-teens core EPS decline; stronger LOE-affected and mature-portfolio revenue is partly offset by Albumin and QDENGA weakness.

  • FY2026 restructuring costs are forecast at JPY 160B; CAPEX guidance is JPY 330B–380B and annual dividend guidance remains JPY 204 per share.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Takeda Pharmaceutical Company earnings date

Logotype for Takeda Pharmaceutical Company Limited
Jefferies Global Healthcare Conference17 Nov, 2026
Takeda Pharmaceutical Company
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Takeda Pharmaceutical Company earnings date

Logotype for Takeda Pharmaceutical Company Limited
Jefferies Global Healthcare Conference17 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Takeda Pharmaceutical Company Limited, founded in 1781, is a research-based global company. The Company's segment is engaged in the research and development, manufacturing and marketing of pharmaceutical products. Through its global presence in over 70 countries, the Company offers a range of products to meet unmet medical needs in a variety of therapeutic areas, including gastroenterology, oncology and neuroscience, among others. The Company's business unit includes Gastroenterology Business Unit, Oncology Business Unit and General Medicines Business Unit. GBU's focus is on creating new value in GI diseases to enhance the lives of patients and their families. OBU's focus is on building a portfolio with the potential to serve patients worldwide that address unmet cancers. GMBU focuses on providing innovative treatment options for patients in such disease areas as internal medicine, respiratory, renal and central nervous system.